Shares of Allogene Therapeutics Inc. (NASDAQ:ALLO) leapt 36% higher to $42.12 on Thursday after limited data from a small number of relapsed/refractory (r/r) non-Hodgkin lymphoma patients showed a combination of the company's anti-CD19 allogeneic CAR T candidate, ALLO-501, and an anti-CD52 monoclonal antibody, ALLO-647, met with an overall response rate of 78%.
New data show Johnson & Johnson’s Erleada (apalutamide) and Xtandi (enzalutamide) from Pfizer Inc. and Astellas Pharma Inc. both prolonged overall survival in men with non-metastatic castration-resistant prostate cancer (nmCRPC).
New and updated preclinical and clinical data to be presented by biopharma firms at the American Society of Clinical Oncology’s annual meeting May 29-31, including: Allogene, Arvinas, Astrazeneca, Exelixis, Eli Lilly, Galera, Heat, Helsinn, Immunogen, Innate, Innovent, Inovio, Janssen, Kyowa, Legend, Marker, MEI, Merck, Targovax, Tarveda, Tiziana, Vaximm, Xencor.
CYBERSPACE – At the virtual annual meeting of the American Society of Gene and Cell Therapy, CAR T cells were the subject of both historical overviews and cutting-edge research alike.
The activity of many proteins is controlled through phosphorylation by kinases and dephosphorylation by phosphatases. Overactive kinases are one of the major drivers of tumors and, as a result, kinase inhibitors are a mainstay of oncology drug development. But “activation of the brakes, the phosphatases, could be equally therapeutically viable for the treatment of a broad range of cancers” to kinase inhibition, Goutham Narla told the audience at the 2020 American Association for Cancer Research (AACR) meeting.
CYBERSPACE – At a series of new drugs on the horizon sessions at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting I, a variety of companies presented preclinical and clinical data for promising early stage oncology products.
DUBLIN – Thrive Earlier Detection Corp. and its academic and clinical collaborators have provided a first glimpse at the utility of a liquid biopsy test as a screening tool for picking up cancers in an asymptomatic population. In an interim one-year readout of data from the prospective five-year DETECT-A study in 10,000 women, an early version of Thrive’s Cancerseek test picked up 26 cancers ahead of standard-of-care screening, while the latter modality picked up another 24 cancers that Cancerseek missed.
New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research’s Virtual Annual Meeting, including: Karus, Noxxon, Oric, Syndax, Tarveda, Trovagene.
New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research’s Virtual Annual Meeting, including: Alligator, Alpine Immune, Aptose, Astrazeneca, Compugen, Iteos, Macrogenics, Merck, Rgenix, Ribon, Sutro, Theratechnologies, Vaccinex, Verastem.
New and updated preclinical and clinical data presented by biopharma firms at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC Virtual), including: Amarin, Mesoblast, Resverlogix.
RSS
